COMMUNIQUÉS West-GlobeNewswire

CVRx to Present at the Canaccord Genuity 44th Annual Growth Conference

31/07/2024 - 22:27

MINNEAPOLIS, July 31, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the Canaccord Genuity 44 th Annual [...]

Ocugen, Inc. Announces Proposed Public Offering of Common Stock

31/07/2024 - 22:15

MALVERN, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced [...]

Beyond Air® Publishes Peer-Reviewed Journal Article in Scientific Reports with Clinical Data Showing Nitric Oxide was Safe and Beneficial Adjunct Therapy for Subjects with Viral Pneumonia

31/07/2024 - 22:15

GARDEN CITY, N.Y., July 31, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of [...]

DLH Reports Fiscal 2024 Third Quarter Results

31/07/2024 - 22:15

Debt Reduction Continues as Company Sees Increased Bid Activity to Close Out Fiscal 2024 ATLANTA, July 31, 2024 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of [...]

QIAGEN delivers solid performance and exceeds outlook for Q2 2024

31/07/2024 - 22:06

Q2 2024: Net sales of $496 million (+0% actual rates, +1% constant exchange rates, CER); net loss per share of $0.83 but adjusted diluted EPS of $0.55 // Net sales at CER of $502 million ahead of outlook for at least $ [...]

Teladoc Health Reports Second Quarter 2024 Results

31/07/2024 - 22:05

PURCHASE, NY, July 31, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the three months ended June 30, 2024 (“Second [...]

Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights

31/07/2024 - 22:05

COVALENT-111 Phase 2b on track for Q4 2024 readout COVALENT-112 Phase 2a on track for Q4 2024 readout Announcement of the third program in obesity on track for Q3 2024 REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE [...]

Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024

31/07/2024 - 22:05

REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced [...]

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

31/07/2024 - 22:05

- IMM-1-104 Fast Track designation now granted for the treatment of both first and second-line pancreatic ductal adenocarcinoma (PDAC); provides potential to accelerate IMM-1-104’s path to U.S. FDA submission for PDAC [...]

Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations

31/07/2024 - 22:05

SILVER SPRING, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced the appointment of Ryan Marques, Ph.D, MBA as Vice President of [...]

Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC

31/07/2024 - 22:05

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has entered into a $25 million common stock purchase agreement (the “Purchase [...]

AVITA Medical Expands Portfolio with Unique Dermal Matrix to Advance Wound Care

31/07/2024 - 22:05

Exclusive development and distribution agreement with Regenity Biosciences provides AVITA Medical with the commercialization rights to a unique collagen-based dermal matrix following 510(k) clearance VALENCIA, Calif., [...]

Avadel Pharmaceuticals Announces First Patient Dosed in Phase 3 REVITALYZ™ Trial of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

31/07/2024 - 22:05

DUBLIN, July 31, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that the first patient has been [...]

MIMEDX Announces Launch of HELIOGEN™ Fibrillar Collagen Matrix

31/07/2024 - 22:02

Limited market release marks first xenograft addition to Company’s portfolio of leading Wound and Surgical products MARIETTA, Ga., July 31, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “ [...]

Standard BioTools Announces Senior Leadership Changes

31/07/2024 - 22:02

Alex Kim, Chief Operating Officer and Standard BioTools Co-Founder, to Serve as interim Chief Financial Officer Following Departure of Jeffrey Black on August 31, 2024 Industry Veteran Sean Mackay Named Chief Business [...]

Bionano to Present at the Canaccord Genuity 44th Annual Growth Conference

31/07/2024 - 22:01

SAN DIEGO, July 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at the Canaccord Genuity 44 th [...]

MIMEDX Announces Second Quarter 2024 Operating and Financial Results

31/07/2024 - 22:01

Net Sales of $87 Million Grew 7% Year-Over-Year for the Second Quarter Second Quarter GAAP Net Income and Earnings Per Share were $18 Million and $0.12 , Respectively Second Quarter Adjusted EBITDA was $20 Million, or [...]

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

31/07/2024 - 22:01

Evorpacept is the first CD47 blocker to show durable clinical benefit and a well-tolerated safety profile in a prospective randomized trial Evorpacept combination achieved a confirmed overall response rate (ORR) of 40.3 [...]

PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time

31/07/2024 - 22:01

PRINCETON, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets [...]